Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report
Biologic agents are a beneficial therapy for juvenile idiopathic arthritis (JIA). However, there is a lack of evidence with regard to management of these agents for JIA patients who undergo kidney transplantation (KTx). A 36-year-old woman with JIA who was treated with tocilizumab targeting interleukin-6 (IL-6) receptor underwent ABO-incompatible kidney transplantation (ABOi KTx). To prevent over-immunosuppression, tocilizumab was discontinued before ABOi KTx. Rituximab, tacrolimus, mycophenolate mofetil, everolimus, and methylprednisolone were used for immunosuppression.
Source: Transplantation Proceedings - Category: Transplant Surgery Authors: S. Ishikawa, M. Tasaki, T. Kuroda, D. Kobayashi, K. Saito, Y. Nakagawa, M. Ikeda, K. Takahashi, Y. Tomita Tags: Original Contributions: Case Reports Source Type: research
More News: Actemra | Arthritis | Kidney Transplant | Kidney Transplantation | Methylprednisolone | Prograf | Rheumatology | Rituxan | Tacrolimus | Transplants | Urology & Nephrology